Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > CAR-T Partner deals in the works

<< Previous

Bullboard Posts

Next >>

Comment by canadafanon Jun 18, 2021 7:27pm

309 Views

Post# 33415658

RE:CAR-T Partner deals in the works

Not sure what you listened to, but the most recent biotch/ chat @ no time did Matt say " nothing until next year"
he did say however there were a number of MTA requests , which they hope to capitalize on.
that being the Car- t data.

<< Previous

Bullboard Posts

Next >>

Corus reports Q1 profit drop in the face of falling revenue